Your hope is coming true. There are 15 new drugs in the pipeline. CagriSema, retatrutide, survodutide, amycretin, MariTide (maridebart cafraglutide), PF-08653944 (MET-097i), KAI-7535 (HRS-7535), KAI-4729 (HRS-4729), VK2735, pemvidutide, ecnoglutide, petrelintide, eloralintide, cagrilintide, and monlunabant.

Also, Novo Nordisk’s data exclusivity for semaglutide expired in Canada on January 4, 2026, so people in border states in the US should be able to get that one very cheap soon.